Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Participants in the Diabetes Prevention Program (DPP) randomized to intensive lifestyle modification (ILS) or metformin had a significantly reduced incidence of diabetes compared with those randomized to placebo, yet most were still at risk because they had pre-diabetes. We explored the effect of baseline characteristics, weight change, ILS, and metformin on regression from pre-diabetes to the lowest-risk state of normal glucose regulation (NGR) defined by American Diabetes Association criteria. RESEARCH DESIGN AND METHODS: The DPP was a prospective randomized trial. Cox proportional hazards modeling was used to identify predictors of regression from pre-diabetes to NGR over 3 years of follow-up. RESULTS: Lower baseline fasting (hazard ratio 1.52, P < 0.01) and 2-h (1.24, P < 0.01) glucose predicted regression to NGR, as did younger age (1.07, P < 0.01) and greater insulin secretion (1.09, P = 0.04). ILS (2.05, P < 0.01) and weight loss (1.34, P < 0.01) had significant and independent effects on regression. A nonsignificant trend for regression was also observed for metformin (1.25, P = 0.06), male sex (1.17, P = 0.08), and insulin sensitivity (1.07, P = 0.09). In those entering the study with both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), male sex and insulin sensitivity predicted regression to isolated IFG, whereas ILS, metformin, female sex, and greater insulin secretion predicted regression to isolated IGT. CONCLUSIONS: Insulin secretion, and other biologic processes retained with younger age, are key in restoring NGR in people with pre-diabetes. However, NGR may also be attained through weight loss and additional aspects of ILS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Diabetes Prevention Program (DPP), greater baseline β-cell function and insulin sensitivity contributed independently to the restoration of NGT following lifestyle changes ( 65 , 66 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“ILS and metformin both have been shown to be effective strategies for diabetes prevention, but in the DPP only ILS restored NGR significantly more frequently than did placebo (2).”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundPrevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · cited 1×
“3 he prevalence of type 2 diabetes increased 61% between 1990 and 2001 (1), and by 2005, it affected nearly 21 million Americans (www.”
BackgroundFollow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 1×
“Insulin sensitivity and secretion are integrally related and the deterioration of each is felt to be requisite in the development of type 2 diabetes (21).”
BackgroundWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“Nevertheless, longitudinal data (22) clearly demonstrate the failure of the -cell as the seminal event in this process.”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundEffect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citation
Cited by
Items 101–200 of 209
Wang, H., Liu, T., Qiu, Q., Ding, P., He, Y., & Chen, W. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120201237 · Cited by 15
“Many studies have shown that fortunately, lifestyle or medication interventions at the pre-diabetes stage can delay or prevent the progression of pre-diabetes to T2DM [5–10].”
BackgroundGalderisi, A., Tricò, D., Pierpont, B. M., Shabanova, V., Samuels, S. L., Man, C. D., Galuppo, B., Santoro, N., & Caprio, S. (2020) · Diabetes Care · doi:10.2337/dc20-0445 · Cited by 17
Liu, Y., Guo, H., Wang, Q., Chen, J., Xuan, Y., Xu, J., Liu, Y., Sun, K., Gao, Q., Sun, Z., et al. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.12.009 · Cited by 15
Physical Activity for the Prevention of Cardiometabolic Disease
Bull, F., Goenka, S., Lambert, E. V., & Pratt, M. (2017) · doi:10.1596/978-1-4648-0518-9/ch5 · Cited by 22
“(Perreault et al. 2009, Weinstein et al. 2004) Collectively, these studies provide strong evidence that behavioral interventions, and specifically those aimed at encouraging regular physical activity, are effective for tackling diabetes at the population level including in developing countries.”
BackgroundHong, J., McNeill, A. M., He, J., Chen, Y., & Brodovicz, K. G. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4007 · Cited by 13
Impact of weight gain on the evolution and regression of prediabetes: a quantitative analysis
Nakasone, Y., Miyakoshi, T., Sato, Y., Yamauchi, K., Hashikura, R., Takayama, M., Hirabayashi, K., Koike, H., & Aizawa, T. (2016) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2016.118 · Cited by 13
Bergman, M., Jagannathan, R., Buysschaert, M., Medina, J. L., Sevick, M. A., Katz, K., Dorcely, B., Roth, J., Chetrit, A., & Dankner, R. S. (2017) · Endocrine · doi:10.1007/s12020-017-1236-2 · Cited by 13
Nah, E., Chu, J., Kim, S., Cho, S., & Kwon, E. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.11.017 · Cited by 17
Galderisi, A., Tricò, D., Man, C. D., Santoro, N., Pierpont, B. M., Groop, L., Cobelli, C., & Caprio, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz207 · Cited by 12
Andellini, M., Manco, M., Esposito, M. T., Tozzi, A. E., Bergman, M., & Ritrovato, M. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01963-3 · Cited by 12
Allende-Vigo, M. Z. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182211bae · Cited by 17
“Predictors of regression to normal glucose tolerance in the DPP Study follow-up analysis were lower baseline fasting glucose, younger age, greater insulin secretion, and weight loss.(21) In the Indian DPP, there was a relative risk reduction of 28.”
Giráldez‐García, C., Soriano, L. C., Albaladejo, R., Franch‐Nadal, J., Mata‐Cases, M., Díez‐Espino, J., Artola, S., Serrano, R., Regidor, E., for the PREDAPS Study Group, et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87838-z · Cited by 13
Prevention of type 2 diabetes: what is the right target population?
Williamson, D. A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1535896 · Cited by 13
Jagannathan, R., & Bergman, M. (2017) · Diabetic Medicine · doi:10.1111/dme.13370 · Cited by 11
Obesity and Insulin Resistance Are the Central Issues in Prevention of and Care for Comorbidities
Govers, E. (2015) · Healthcare · doi:10.3390/healthcare3020408 · Cited by 11
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi, A., Weiss, L., Besançon, A., Stremler, N., Reix, P., Wizla, N., Lustre, A., Rames, C., Tatopoulos, A., Périsson, C., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf099 · Cited by 9
Bahadoran, Z., Mirmiran, P., & Azizi, F. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00257-7 · Cited by 12
“Adherence to a healthy low-calorie, low-fat diet, and moderate physical activity level (PAL) results in Pre-DM remission by two-folds [9].”
BackgroundRodríguez-Pérez, M., Orozco-Beltrán, D., Gil-Guillén, V., Domínguez-Coello, S., Almeida-González, D., Brito-Díaz, B., Marcelino-Rodriguez, I., Carratalá-Munuera, M., Gómez-Moreno, N., Navarro-Pérez, J., et al. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.009 · Cited by 7
Coppell, K. J., Freer, T., Abel, S. L., Whitehead, L., Tipene‐Leach, D., Gray, A. R., Merriman, T. R., Sullivan, T. A., Krebs, J. D., & Perreault, L. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-033358 · Cited by 8
Self-citationDagogo-Jack, S. E., Brewer, A., Owei, I., French, L., UMEKWE, N. A., Rosenthal, R. H., & Wan, J. Y. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000899 · Cited by 9
Normalization of glucose intolerance in first-degree relatives of patients with type 2 diabetes
Janghorbani, M., & Amini, M. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.01.025 · Cited by 11
Della, L. J., King, K. M., & Ha, J.-P. (2013) · Journal of Nursing Measurement · doi:10.1891/1061-3749.21.2.210 · Cited by 8
Kim, S. H., Park, T. S., & Jin, H. Y. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.06.003 · Cited by 8
“The 75 g OGTT is well known to be helpful for the diagnosis of diabetes, especially when patients show an IFG state; however, it is not clear why a 75 g dose of glucose is used and whether this amount is adequate for every IFG patient.”
MethodInfluentialOgata, C., Ohmoto‐Sekine, Y., Tanabe, M., Iwao, A., Hsieh, S. D., Amakawa, K., Matsumoto, N., Ogawa, K., Arimoto, S., Okuda, C., et al. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1585 · Cited by 9
Edeoga, C., Asuzu, P., Wan, J. Y., & Dagogo-Jack, S. E. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004545 · Cited by 7
Wang, Y., Sandforth, A., von Schwartzenberg, R. J., Ganslmeier, M., Cheng, Y., Sandforth, L., KATZENSTEIN, S., Machann, J., Schick, F., Kantartzis, K., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156430 · Cited by 6
Shakya, P., Shrestha, A., Karmacharya, B. M., Shrestha, A., Kulseng, B. E., Skovlund, E., & Sen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064516 · Cited by 6
An Outpatient-Based Clinical Program For Diabetes Prevention: an Update
Swanson, C. M., Bersoux, S., Larson, M. H., Aponte-Furlow, R. T., Flatten, S. S., Olsen, C. L., LaRosa, C. S., Verona, P. M., Jameson, K. A., & Cook, C. B. (2011) · Endocrine Practice · doi:10.4158/ep11226.or · Cited by 6
Defining prediabetes remission as a distinct prevention endpoint
Birkenfeld, A. L., Perreault, L., Schmidt, M. I., Schwarz, P. E. H., Zoungas, S., Gong, Q., Chan, J. C. N., Mohan, V., Tuomilehto, J., & Bergman, M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00360-2 · Cited by 5
Self-citationObura, M., Beulens, J. W. J., Slieker, R. C., Koopman, A. D. M., Hoekstra, T., Nijpels, G., Elders, P. J. M., Dekker, J. M., Koivula, R. W., Kurbasic, A., et al. (2020) · Diabetic Medicine · doi:10.1111/dme.14428 · Cited by 5
Bevan, G., Poli, C. D., Keng, M. J., & Raine, R. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033483 · Cited by 5
Vargas, M. C., Pineda, G., Talamantes, V., Toledo, M. J. L., Owen, A. L., Carcamo, P., Gibbert, W. S., Ackermann, R. T., Kandula, N. R., Cameron, K. A., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107216 · Cited by 6
Ruan, C., Li, Y., Ran, Z., Liu, G., Li, W., Zhang, X., Shao, S., & Li, Y. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s451189 · Cited by 5
“4 8 The swiftly escalating global prevalence of prediabetes, coupled with its associated complications, positions blood glucose disorders as a significant public health issue.”
BackgroundNovel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi, A., Tricò, D., Lat, J., Samuels, S. L., Weiss, R., Name, M. A. V., Pierpont, B. M., Santoro, N., & Caprio, S. (2023) · JCI Insight · doi:10.1172/jci.insight.165709 · Cited by 7
Metformin: Midlife maturity, maiden charm
Kalra, S., Dhamija, P., & Das, A. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.103028 · Cited by 6
“Apart from its glycemic effects in type 2 diabetes, for which it is approved, it is used in other forms of diabetes such as pre-diabetes,[1] type 1 diabetes[2] and gestational diabetes mellitus.”
BackgroundSerum uric acid and prediabetes progression and regression: a retrospective cohort study
He, Y., Ye, M., Xia, Y. Y., Zhong, Z., & Li, Q. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae183 · Cited by 4
Feng, C., Wang, X., & Luo, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1668021 · Cited by 4
Population-Level Approaches to Preventing Type 2 Diabetes Globally
Siegel, K. R., & Albright, A. L. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.010 · Cited by 6
Shakya, P., Bajracharya, M., Skovlund, E., Shrestha, A., Karmacharya, B. M., Kulseng, B. E., Sen, A., Steinsbekk, A., & Shrestha, A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20065054 · Cited by 7
Mandal, N. A., Asuzu, P., Stentz, F. B., Wan, J. Y., & Dagogo-Jack, S. E. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231184228 · Cited by 4
“35,39 The CASPID study will evaluate pre-intervention (baseline) and postint-ervention changes in targeted lipidomic profiles as potential predictors and correlates of the various glycemic outcomes.”
BackgroundTu, L., Hu, H., Zhou, X., Zhang, H., Liu, X., Yang, D., & He, Y. (2024) · European journal of medical research · doi:10.1186/s40001-024-01669-y · Cited by 4
“Previous epidemiological studies have provided evidence indicating that regression to normoglycemia may be related to various factors, including age, insulin secretion, beta-cell function, baseline fasting plasma glucose (FPG), obesity, and fasting triglycerides [13–16].”
BackgroundKabadi, U. M. (2013) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2013.33019 · Cited by 6
“tions [1-8] have delayed the progression of prediabetes (impaired fasting glucose and impaired glucose tolerance)”
BackgroundPrediabetes in Transition: Insights from the Tehran Lipid and Glucose Study
Bahadoran, Z., & Hosseinpanah, F. (2025) · Intern J Endocrinol Metab · doi:10.5812/ijem-166455 · Cited by 4
“Evidence suggests that lower fasting glucose, greater insulin secretion, younger age, weight loss, and adherence to lifestyle interventions are associated with a higher probability of reverting to NGR (26, 28).”
Yang, Z., Zhu, S., Lyu, C.-A., Fu, H., Chen, W., Qiu, X., Zhang, W., Yu, T., Yang, M., Zhang, Z. Y., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.02.006 · Cited by 6
The contribution of unrecognized factors to the diabetes epidemic
Bergman, M., Jagannathan, R., & Sesti, G. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3315 · Cited by 3
Bahadoran, Z., Mirmiran, P., Azizi, F., & Hosseinpanah, F. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.08.024 · Cited by 3
Lee, M. J., Bae, J. H., Khang, A. R., Yi, D., Kim, J. Y., Kim, S. H., Kim, D. H., Kang, D., Park, S., Jeon, Y. K., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae632 · Cited by 4
Masumi, M., Bahadoran, Z., Mirmiran, P., Khalili, D., Sarvghadi, F., & Azizi, F. (2024) · BMC Public Health · doi:10.1186/s12889-024-20680-w · Cited by 4
Amorosa, L. F., Lee, E. J., & Swee, D. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1160-8.10034-x · Cited by 6
Mo, Z., Hu, H., Han, Y. Y., Cao, C., & Zheng, X. (2024) · Scientific Reports · doi:10.1038/s41598-023-50539-w · Cited by 3
Ledford, C. J. W., Fulleborn, S. T., Jackson, J. T., Rogers, T., & Samar, H. (2021) · Health Expectations · doi:10.1111/hex.13245 · Cited by 3
Mshelia, D. S., Adamu, S., & Gali, R. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96549 · Cited by 6
Kabisch, S., Meyer, N. M. T., Honsek, C., Kemper, M., Gerbracht, C., Arafat, A. M., Dambeck, U., Osterhoff, M. A., Weickert, M. O., & Pfeiffer, A. F. H. (2022) · Nutrients · doi:10.3390/nu14224721 · Cited by 3
Onishi, Y., Hayashi, T., Satō, K., Leonetti, D. L., Kahn, S. E., Fujimoto, W. Y., & Boyko, E. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.045 · Cited by 4
Self-citationBahadoran, Z., Mirmiran, P., Azizi, F., & Ghasemi, A. (2024) · Bioimpacts · doi:10.34172/bi.2024.29917 · Cited by 2
Yang, H., Liu, Y., Huang, Z., & Deng, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463650 · Cited by 3
Diabetes-related weight change in a Canadian First Nation cohort
Riediger, N. D., Lukianchuk, V., Roulette, J., Lix, L., Elliott, L. J., & Bruce, S. G. (2017) · International Journal of Circumpolar Health · doi:10.1080/22423982.2017.1340548 · Cited by 2
Dannecker, C., Hummel, J., & Fritsche, L. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00593-z · Cited by 4
Dorcey, C. (2013) · Lincoln (University of Nebraska) · Cited by 2
Measuring the sweet smell of success in diabetes management.
Unger, J. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.08.04 · Cited by 2
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2014) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2014.20.22-35 · Cited by 2
The STOP DIABETES study: when prevention works
Bonaventura, A., & Montecucco, F. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01309-6 · Cited by 2
Bessell, E., Markovic, T., Caterson, I. D., & Fuller, N. R. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.05.004 · Cited by 2
Prädiabetes und Diabetessubphänotypen – Konsequenzen für die Prävention
Wagner, R. J., & Fritsche, A. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00594-y · Cited by 2
Intervention at the very early stage of type 2 diabetes
Aizawa, T., & Funase, Y. (2010) · Diabetologia · doi:10.1007/s00125-010-1997-0 · Cited by 2
Perreault, L. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_2 · Cited by 1
“05), not metformin, is useful in achieving normoglycemia in people with prediabetes [84].”
BackgroundSelf-citationZhang, K., Chen, L., Deng, Z., Rong, R., Xu, L., Xu, L., Zeng, S., & Hu, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1546202 · Cited by 1
Zheng, Z., Song, Y., Cui, K., He, J., Bian, X., Song, C., Dong, Q., Zhu, C., Fu, R., & Dou, K. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03123-1 · Cited by 1
“…heterogeneous population where transient hyperglycemia may reflect compensatory mechanisms or early metabolic dysregulation, as evidenced by longitudinal data reported that 54% of patients with ADA-defined pre-diabetes returned to normoglycemia at least once during the 3-year follow-up period [32].”
Type 2 diabetes prevention across the life course
Wang, Y., Sargent, J. L., Mathieu, C., Arreola, E. V., Perreault, L., Loos, R. J. F., Lim, L., Sandforth, L., Hanson, R. L., Kullmann, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04550-z · Cited by 1
“Among individuals who experienced at least 5% weight loss through lifestyle intervention, those who achieved remission of prediabetes exhibited a larger reduction in visceral adipose tissue volume and greater improvements in insulin sensitivity than those who did not experience remission 29,37 .”
Self-citationGottwald‐Hostalek, U., & Mustafina, S. V. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1070 · Cited by 1
Prädiabetes als therapeutische Herausforderung in der Inneren Medizin
Kantartzis, K., Fritsche, A., & Birkenfeld, A. L. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01546-6 · Cited by 5
Metabolic health and strategies for a Healthier SG
Khoo, J. J. C., Lim, R. L. C., Ng, L. P., Phoon, I. K. Y., Gani, L. U., Puar, T. H. K., How, C. H., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-157 · Cited by 1
“Evidence shows that prediabetes can be reversed by lifestyle modification with or without medications such as metformin, [60] acarbose [61] and pioglitazone.”
Prediabetes in youth: an opportunity to make a difference
Song, S. H. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30255-4 · Cited by 1
Lynam, A. L., Behrens, D. A., Battista‐Dowds, E. M., Gärtner, D., & Harper, P. (2020) · IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi48887.2020.9374358 · Cited by 1
Bower, J. K. (2010) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 3
Unmasking Hidden Dysglycemia: A Mobile OGTT Approach Using Continuous Glucose MonitorsPreprint
Singh, K., Esteve, L., North, P., Beason, A., Hershkovich, L., Chen, B. B., Islam, S. M. M., Bent, B., Cho, P. J., Wang, W. K., et al. (2025) · medRxiv · doi:10.64898/2025.12.14.25341915 · Cited by 2
Phillips, K. C. (2011) · ResearchSpace (University of KwaZulu-Natal)
Yakubovich, N. (2012) · MacSphere (McMaster University) · doi:10.71548/20534
Rimareix, F., & Bauduceau, B. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.04.001
Albai, O., & Timar, R. Z. (2012) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/v10255-012-0004-6
“To reduce the CMR of these people preventive measures are required as early as possible, represented primarily by lifestyle modification (diet and exercise) [17, 18].”
BackgroundNakade, Y., & Yoneda, M. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.2028
“The PPR group also indicated that the use of ILI predicts regression to NGR, independent of weight loss.”
BackgroundInfluentialAmi, N. D. (2011) · Library and Archives Canada (Government of Canada)
Intensification of Type 2 Diabetes in Adolescents: Guess What? Exercise Wins!
Unger, J. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.164
DiMaria, L. (2015) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-dimaria-lisa-2015 · Cited by 1
Saito, I. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.89.2015.tde-17112015-170114
Optimizing the Exercise Drug for Metabolic Rehabilitation
Braun, B. (2015) · Kinesiology Review · doi:10.1123/kr.2014-0084
How Family Physicians Practice the Principle of Remission Along the Glycemic Continuum
Fulleborn, S. T., Crawford, P. F., Jackson, J. T., & Ledford, C. J. W. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720977744
Overview on Glucose Tolerance Testing in Primary Health Care
Algaows, F. S., Obaid, H., Sharyah, S. M. A., Alshehri, D. A., Alharbi, Y. H., Althawab, H. A., Adnan, A. M., Bokhari, A. N., Alkhamis, M. A., Alansari, A. A., et al. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i46b32910
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1017 · Cited by 1
Mathioudakis, N. N., Everett, E. M., Alhajri, N., Abusamaan, M. S., Lee, C. J., Kane, B., & Dobs, A. S. (2019) · doi:10.2196/preprints.13706
Lifestyle factors and reversion to normoglycaemia by prediabetes type in PREDAPS study.Preprint
Soriano, L. C., Giráldez‐García, C., Albadalejo, R., Franch‐Nadal, J., Mata‐Cases, M., Díez‐Espino, J., Artola, S., Serrano, R., & Regidor, E. (2019) · doi:10.21203/rs.2.17828/v1
Diabetes Prevention on a Research and Clinical Practice Continuum
Delahanty, L. M. (2023) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106231169690
Chai, X., Wang, Y., Wang, J., Gong, Q., Zhang, J., & Shao, R. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0489 · Cited by 1
Iwańska, A., Wójcik, M., Szczudlik, E., Stępniewska, A., & Starzyk, J. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2023-8-9 · Cited by 1
“The patients who reverted also had lower LDL levels than patients who had persistent IGT, in both pre-and post-intervention periods (15).”
BackgroundInfluentialZhang, K., Chen, L., Deng, Z., Rong, R., Xu, L., Xu, L., Zeng, S., & Hu, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4945577/v1
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch04
Reversal of Prediabetes and Restoration of Normal Glucose Regulation
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch08
Lagger, G., & Kistler, V. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.06.004
Metadata
- Authors
- Perreault, L., Kahn, S. E., Christophi, C. A., Knowler, W. C., Hamman, R. F., & the Diabetes Prevention Program Research Group
- Affiliations
- University of Colorado Anschutz (US)
- University of Washington (US)
- George Washington University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Colorado School of Public Health (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-07-08
- Volume
- 32
- Issue
- 9
- Pages
- 1583-1588
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732165
- OpenAlex
- W2109748090
- Cited by
- 209
- References
- 25
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 14 · 2019: 12 · 2018: 15 · 2017: 14 · 2016: 8 · 2015: 11 · 2014: 13 · 2013: 14 · 2012: 9
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- prediabetes, Diabetes Prevention Program, intensive lifestyle intervention, metformin, weight loss, insulin secretion, insulin sensitivity, impaired fasting glucose, impaired glucose tolerance
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Life Style, Male, Metformin, Middle Aged, Prediabetic State, Sex Factors, Weight Loss, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.